GLYCOPYRROLATE is a synthetic quaternary ammonium compound which is an anticholinergic agent. It has been used to control gastric acidity since its introduction as ROBINOL| by A.H. Robins Company in 1960. Most previous clinical reports have related to its use in the management of peptic ulcers and other disorders associated with gastric hyperacidity and it appears that the literature on its value in anaesthetic practice is scanty.
A generally randomized sample of 98 patients made up of 32 males and 66 females with ages ranging from 16 to 73 years were included in tiffs study. They were undergoing elective intra-abdominal operations under general anaesthesia. There were 49 patients in each of the glycopyrrolate and the atropine groups. The drugs were provided in identical bottles, each bottle bearing a special serial number for later identification. Table I shows the age distribution of the two groups of patients. Table II shows the distribution by type of operation and the number of patients in each group. All the patients for cholecystectomy were given a premedication intramuscularly consisting of meperidine 50 to 100 mg (the maiority receiving the lower dosage) and either atropine 0.4 mg or glycopyrrolate 0.9. mg, from the coded supply, 45 minutes to one hour before operation. Anaesthesia was induced with thiopentone 2.5 per cent in a dose ranging from 250 mg to 500 mg, most patients receiving the lower dose range, and was then maintained with nitrous oxide and oxygen in the semi-closed circle absorber system. Intravenous meperidine 10 to 20 mg was administered intena~ittently to provide analgesia. Dimethyl tubocurarine iodide was the muscle relaxant for all the 98 patients. muscarinic effects of neostigmine methylsulphate, double the dose of the same unknown anticholinergic used for the premedication was administered intravenously five minutes prior to neostigmine. The other patients had moqohine 10 to 15 mg and the unknown anticholinergic for premedication. Dimethyl tubocurarine iodide was again the muscle relaxant used. Anaesthesia and analgesia were maintained with nitrous oxide, oxygen and methoxyflurane in a semi-closed circle system with the absorber in circuit. Nine patients in the atropine group and seven in the glycopyrrolate group had methoxyflurane. In one patient in the atropine group, anaesthesia was maintained by halothane. Once again, double the premedication dose of the unknowaa anticholinergic was given five minutes prior to administration of neostigmine for the reversal of the muscle relaxant.
Parameters monitored were pulse rate, blood pressure, oral temperature, the electrocardiogram and the size of the pupils. These were recorded before premedication, 45 minutes to 60 minutes after premedication, before induction, after induction, at frequent intervals during the operation, before and for five minutes after the intravenous administration of the anticholinergic drug at the end of operation and before and for five minutes after neostigmine. The pharynx was suctioned before and after extubation or, when the trachea was not extubated, before the patient left the operating room. The amount of saliva suctioned through the transparent tube was assessed clinically, comparing the quantity with what, from one's experience, was usually obtained from atropine and neostigmine reversal.
RESULTS

Pharyngeal secretions
The mouth and pharynx were assessed as moist or dry before premedication was administered and prior to induction. There was no significant difference in the state of the pharynx between the two groups, before premedication was given.
The state of the pharynx before induction in the two groups is shown in Table  III . The results in the two groups are not significantly different. Glycopyrrolate 0.2 mg or atropine 0.4 mg given intramuscularly for premedication produce the same antisialogogue effect on the pharynx. This is consistent with the findings of Wyant and Kao?
The effect of each anticholinergic agent in antagonizing the salivary stimulating effect of neostigmine was assessed fiveminutes after neostigmine administration as:
(a) Dry pharynx (b) Less than average secretions (c) Average secretions (as after atropine and neostigmine) (d) Excessive secretions. Table IV gives the results of this study. Glycopyrrolate is significantly superior to atropine in antagonizing the salivation stimulated by neostigmine. Ramamurthy, Ylagan and Winnie 2 also observed that in their group of patients reversed with a glycopyrrolate-neostignaine mixture, secretions were virtually non-existent. The method of evaluating the volume of secretions in this study has many drawbacks compared ~vith the more accurate method used by Wyant and Dobkin s and more recently by Wyant and Kao. 1 However, with an intubated trachea, their method would have been perhaps more difflcult to employ.
EFFECTS ON PULSE I~ATE
Changes in pulse rate were studied and compared at specific time intervals. These were:
1. Forty-five minutes to one hour after premeditation, or before induction.
2. Two minutes and five minutes after the intravenous administration of the anticholinergic agent (atropine 0.8 mg or glycopyrrolate 0.4 rag). 3. At two minutes and five minutes after the intravenous administration of neostigmine methylsulphate 2.5 mg. 4. Bradycardia within one hour of cessation of anaesthesia. The difference between the mean pulse rates of the two groups before premedication was administered was not significant (t-" 0.6 p > 0.5).
Pulse rate changes 4.5 minutes to 60 minutes after premedication
While the mean changes in pulse rate from premedication level for each group were significant (for atropine, t = 4.4, 48 df, p < 0.01, and for glycopyrrolate, t = 3.0, 47 df, p < 0.01), they were nearly the same for each treatment group. Table V presents the incidence of pulse rate changes for the intervals indicated. x * = 0.4602 (<0.5). 
Pulse rate changes after the intravenous administration of the anti-cholinergic
The incidence of pulse rate changes are shown in Table VI , which suggests that, at two minutes, the glycopyrrolate group exhibited a lesser degree of increase in pulse rate. However, by the five-minute observation, it appears that the greater increase is associated with glycopyrrolate. To examine this finding, the distribution of the patients with pulse rates greater than 100 beats per minute at the five-minute observation is presented in Table VII . This shows that the higher rates are associated with the atropine group. This finding and the results of the two-minute observation are consistent with the observations of Ramamurthy, Shaker and Winnie 4 that glycopyrrolate produces less tachyeardia than atropine.
For completeness, the results before the anticholinergic, and two minutes and five minutes after the anticholinergic were subjected to an analysis of variance for a 2 (DRUGS)-by-3 (TIMES) factorial design with repeated measures across the TIMES factor. The summary is displayed in Table VIII and indicates that the mean pulse rates are significantly different only at the two-minnte observation.
Pulse rate changes after the intravenous administration o[ neostigmine 2.5 mg
The incidence of changes in pulse rates are displayed in Table IX and indicate that the greater decreases in pulse rate are associated with atropine, at least at the two-minute observation. For the absolute pulse rates, an analysis of variance of the same type as described above is summarized in Table X and indicates that the mean pulse rates at both two minutes and five minutes are greater for the glycopyrrolate group, a result also consistent with the finding of Ramamurthy, Shaker and Winnie# There does not appear to be a statistically significant relationship between the two-minute change in pulse rate after administration of the anticholinergic and the two-minute change after neostigmine (for atropine, r = 0.20, p > 0.10, and for glycopyrrolate r = 0.24, p > 0.10).
Post-operative bradycardia
Within the first hour of cessation of anaesthesia 14 patients in the atropine group had developed bradycardia requiring further intravenous injection of the same anticholinergic drug, while only eight patients in the glycopyrrolate group had developed bradyeardia that required treatment. This is not significantly different x" = 2.11 (0.1 < P < 0.25).
BLOOD PRESSURE CHANGES
There was no sig~aificant difference in the blood pressure changes in the" two groups.
Bradycardia During Operation
Three patients in each group required further intravenous anticholinergie during operation, for treatment of sinus bradycardia.
In the atropine group the tTacheae of five patients were not extubated because of inadequate ventilation. Only one in the glycopyrrolate group left the operating room with the tracheal tube in place. A double blind study of 98 patients was undertaken to compare the clinical usefulness of atropine and glycopyrrolate for pre-anaesthetic medication and their relative effectiveness in antagonizing the muscarinic effects of neostigmine methylsulphate given to reverse neuromuscular blockade. Intramuscular administration of atropine 0.4 nag or of glycopyrrolate 0.2 mg produced the same degree of dryness of the pharynx. However, glycopyrrolate was found to be a more potent antagonizer of the increased salivation induced by neostigmine. By intramuscular administration, both drugs produced the same degree of tachycardia, although atropine tended to cause no change in the pulse rate or even to produce bradycardia in a greater number of patients. Administered intravenously, atropine produced a more sigaaificant tachycardia in a large number of patients prior to neostigmine administration, although the protection against a decreased pulse rate from neostigmine is greater ha those patients who received glycopyrrolate. It would appear, therefore, that glycopyrrolate is more effective in antagonizing the muscarinic effects of neostigmine methylsulphate. I~SUME Ce travail avait pour but d'~tablir la valeur clinique de ratropine et du glycopyrrolate en pr~-m~dication, ainsi que d'~tudier leur efficacit~ relative '~ contre-carTer les effets nmscariniques de la n~ostigmine employGe pour renverser la curarisation. Quatre vingt dix huit malades ont ~t6 inclus dans cette ~tude double-insu.
Une iniection intra-musculaire de 0.4 mg d'atropine ou de 0.2 mg de glycopyrrolate produisent le m~me degr~ de sdcheresse du pharynx. Nous avons cependant trouv~ que le glycopyrrolate ~tait un meilleur inhibiteur de la salivation induite par une injection de ndostigmine.
Apr~s administration intra-musculaire, les deux agents produisent le m~me degr~ de tachycardie, mais on a observd que la frdquence n'~tait pas modifi~e, ou m~me qu'elle ~tait ralentie chez un p/us grand hombre de patients ayant eu de l'atropine.
Par voie intra-veineuse, aveaat administration de n~ostigmine, ratropine produisait plus de tachycardie, bien que la protection eontre la bradycardie induite par la prostigmine soit plus grande avec le glycopyrrolate. I1 semble donc que le glycopyrrolate soit sup~rieur ~ l'atropine pour contrecarrer les effets muscariniques de la prostagmine.
